United States: Capitalizing On Collaboration – The President's Precision Medicine Initiative

Last week President Obama marked the one year anniversary of his Precision Medicine Initiative ("PMI") by holding a web-accessible panel discussion where he and interested stakeholders discussed his PMI initiative, its progress and future direction. The President also announced a series of awards, funded by the National Institutes of Health ("NIH"), to build the infrastructure and data collection tools necessary to support the voluntary research cohort who will share health, familial and genetic information. (For more information on the voluntary research cohort, see my prior post of January 26, 2016).

Private-Public Partnerships

The PMI initiative is not limited to the public sector. The President announced that more than 40 private-sector organizations made commitments to PMI. Several public-private partnerships were announced to advance the PMI:

Vanderbilt University in collaboration with Verily (formerly Google Life Sciences) received a grant to lay the foundation for a national community of 1 million or more U.S. volunteers who will partner with researchers to share personal health data;

The NIH and the Health Resources and Services Administration will partner with several health centers to develop, pilot, and refine approaches to engaging underserved and underrepresented individuals, families, and communities to ensure diversity in the data collected to support PMI;

The NIH and the Office of the National Coordinator for Health IT will create "Sync for Science" pilots through an open standards development process with electronic health record developers Allscripts, athenahealth, Cerner, drchrono, Epic and Mckesson;

The Office of the National Coordinator for Health IT and the National Institute of Standards and Technology (NIST), will develop a precision medicine-specific guide to the NIST Cybersecurity Framework to obtain individual input on best practices in security and data management for precision medicine;

The Department of Veterans Affairs and the Department of Defense will expand a participant-driven research cohort with more than 450,000 veteran enrollees; and

The Food and Drug Administration announced the launched its first precisionFDA challenge, which will use the new precisionFDA platform to encourage the genomics community to advance quality standards and achieve more consistent and accurate DNA test results.

Progress for Personalized Medicine

The President's PMI received additional commitments from the private sector to enable patient-access to and the sharing of their data. Several notable examples include, for example: Allscripts, athenahealth, Cerner, crchrono, Epic and Mckesson reported that they will pilot the use of open, standardized application programming interface ("API') to allow patient's access to their own electronic health records;

Carolinas Healthcare System will use a new mobile application that allows patients to view their data from multiple devices. Get My Data is a newly formed not-for-profit group organized to raise public awareness of the right of individuals to access and control their data;

The University of California Health System announced its commitment to giving patients the tools to download their health data from any of the five UC Health medical systems;

Foundation Medicine also announced it is releasing the world's largest, real-world genomics dataset of common and rare pediatric cancers to help develop targeted therapies specifically for pediatric cancer;

IBM and New York Genome Center committed to creating a comprehensive, open cancer data repository, using cognitive insights from IBM's Watson computer system to accelerate cancer research and scale access to precision medicine. The project will begin with a pilot to sequence tumors from 200 cancer patients and compare how different types of sequencing inform and improve cancer care;

Inova Health System, a non-profit healthcare system serving more than 2 million people per year, announced that it will set up a new venture investment fund in excess of $100 million focused exclusively on precision medicine;

Intel also announced a precision medicine initiative, the Precision Medicine Acceleration Program, to develop and release an open source proof of concept for data center infrastructure to support processing, storage, and analysis of large precision medicine data sets; and

Microsoft reported that by the end of this year, it will host large, open genomics data sets on the Microsoft Azure cloud platform at no cost.

Clinical Adoption of Precision Medicine

Progress is not limited to enabling tools for precision medicine. Several significant clinical programs were announced. The Multiple Myeloma Research Foundation (MMRF), announced the MMRF Patient Journey Initiative to educate tens of thousands of patients and their families on the critical steps in the patient journey and the actions they can take to maximize their precision care from diagnosis through the course of their disease. St. Elizabeth Healthcare plans to assess and operationalize the use of a precision medicine pharmacogenomics test to identify the specific type and dosage of medicine to prescribe based on the patient's genetic profile.

Stanford Medicine announced its plant to launching a consultative pharmacogenetics practice in 2016 so that physicians can refer patients with unusual drug responses or with a family history of unusual responses. University of Arizona Health Sciences (UAHS) committed to $22 million to expand the clinical utility of its open-source, patient-centric analytic methods to aid physicians in interpreting disease-associated gene expression changes arising from patients' own DNA blueprint. UAHS also announced the three new precision medicine initiatives. The first is an on-demand "case-based reasoning" system that intelligently searches and analyzes entire databases of electronic medical records. The second is the development of genetic assays to predict an individual's response to therapy and prevention of adverse reactions. The third is a partnership with five other institutions to advance the Sanford Pediatric Genomics Consortium to improve health care decision-making through better understanding and integration of genomic evidence.

And There's More...

Many additional programs were announced by the White House that support and promote the President's initiative. A full summary of the initiatives is found on the White House web page, accessible here. The initiative's scope, depth and commitments from the public and private sectors virtually ensure its success to the benefit of our nation's future health.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions